These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28943551)

  • 21. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Edoxaban is effective in reducing the incidence of asymptomatic phlebographic events following closed-wedge high tibial osteotomy.
    Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Okuyama H; Hirotomi K; Shinohara K; Saito T
    Orthop Traumatol Surg Res; 2017 Dec; 103(8):1193-1196. PubMed ID: 28928048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deep Venous Thrombosis with Decreased Cerebral Blood Flow to the Thalamus was Completely Restored by Factor Xa Inhibitor.
    Shimizu Y; Tsuchiya K; Fujisawa H
    J Stroke Cerebrovasc Dis; 2019 May; 28(5):e39-e43. PubMed ID: 30772162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VTE and anti-coagulation therapy in cancer patients.
    Miyazaki Y; Sase K; Hasegawa K; Morimoto T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):189-191. PubMed ID: 31378809
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Chen J; Zhuang X; Long M; Su C; Wang L
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
    Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
    Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
    Barrios V; Escobar C
    Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Drug-Drug Interaction of Potential Rifabutin-Induced Edoxaban Failure: A Case Report.
    Lanier C; Fuller M; Reece BA
    J Pharm Pract; 2024 Oct; 37(5):1199-1204. PubMed ID: 37931910
    [No Abstract]   [Full Text] [Related]  

  • 31. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA; Snead JA; Cheng-Lai A
    Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
    Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
    Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM; Finks SW
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux.
    Izushi Y; Takami Y; Shiota N; Tetsunaga T; Ookura Y; Shimada K; Egawa T; Kiuchi T; Sato T; Takuma R
    Biol Pharm Bull; 2016; 39(4):516-23. PubMed ID: 27040624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
    Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
    Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.
    Nyberg J; Karlsson KE; Jönsson S; Yin O; Miller R; Karlsson MO; Simonsson U
    CPT Pharmacometrics Syst Pharmacol; 2016 Apr; 5(4):222-32. PubMed ID: 27299709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.